ABSTRACT
The treatment outcomes with conventional second-line chemotherapy or radiotherapy aregenerally very poor for patients with relapsed primary CNS lymphoma (PCNSL). We treated three relapsed PCNSL patients with high-dose cytarabine plus etoposide (CYVE) chemotherapy, and this was followed by autologous stem cell transplantation (ASCT). The salvage CYVE chemotherapy consisted of cytarabine 2g/m2/d on days 2 to 5 in a 3-hour infusion and 50mg/m2/d on days 1 to 5 in a 12-hourinfusion, and etoposide 200mg/m2/d on days 2 to 5 in a 2-hour infusion. After two cycles of CYVE chemotherapy, two patients achieved a complete response (CR), and one patient achieved a partial response (PR). All three patients experienced febrile neutropenia and grade 4 thrombocytopenia with the CYVE chemotherapy. However, the hematologic toxicities were well managed without any complications. The conditioning regimen for ASCT consisted of BCNU 300mg/m2 on day -7, etoposide 100mg/m2 on days -6 to -3, cytarabine 100mg/m2 on days -6 to -3, and cyclophosphamide 35mg/kg on days -6 to -3 (BEAC). After ASCT, the patient who initially showed a PR with CYVE chemotherapy then achieved a CR. At the time of this report, one patient remained alive in CR for 41 months after CYVE chemotherapy. The remaining two patients experienced relapse 5 months and 4 months after ASCT, respectively, and they ultimately died of disease progression 18 months and 8 months after ASCT, respectively. In our cases, the CYVE chemotherapy+ASCT was well tolerated, and this induced the complete disappearance of the tumor, and one patient showed prolonged disease-free survival. CYVE chemotherapy+ASCT could be a treatment option for relapsed PCNSL.
Subject(s)
Humans , Anemia, Hemolytic, Autoimmune , Carmustine , Cyclophosphamide , Cytarabine , Disease Progression , Disease-Free Survival , Drug Therapy , Etoposide , Febrile Neutropenia , Lymphoma , Radiotherapy , Recurrence , Stem Cell Transplantation , Stem Cells , Thrombocytopenia , Waldenstrom MacroglobulinemiaABSTRACT
Posttransplant lymphoproliferative disorder (PTLD) is one of the most serious complication occuring after solid organ transplantation. In general, mucosa-associated lymphoid tissue (MALT) lymphoma of stomach has not been considered to be part of this spectrum, because most of the MALT lymphoma are associated with not EBV but H.pylori. Until now, there have been only a few cases of MALT lymphoma after transplantation. We report case of gastric MALT lymphoma following renal transplantation and review the reported cases in the literatures.